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Background and aims: Studies report that both high and low total cholesterol (TC) elevates SAH risk.
There are few prospective studies on high-density lipoproteins (HDL-C) and low-density lipoproteins
(LDL-C), and apparently none concerns apolipoproteins A and B. We aimed to clarify the association
between lipid profile and SAH risk.
Methods: The National FINRISK study provided risk-factor data recorded at enrolment between 1972 and
2007. During 1.52 million person-years of follow-up until 2014, 543 individuals suffered from incident
hospitalized SAH or outside-hospital-fatal SAH. Cox proportional hazards model was used to calculate
the hazard ratios and multiple imputation predicted ApoA1, ApoB, and LDL-C values for cohorts from a
time before apolipoprotein-measurement methods were available.
Results: One SD elevation (1.28mmol/l) in TC elevated SAH risk in men (hazard ratio (HR) 1.15 (95% CIs
1.00e1.32)). Low HDL-C levels increased SAH risk, as each SD decrease (0.37mmol/l) in HDL-C raised the
risk in women (HR 1.29 (95% CIs 1.07e1.55)) and men (HR 1.20 (95% CIs 1.14e1.27)). Each SD increase
(0.29 g/l) in ApoA1 decreased SAH risk in women (HR 0.85 (95% CIs 0.74e0.97)) and men (HR 0.88 (95%
CIs 0.76e1.02)). LDL-C (SD 1.07mmol/l) and ApoB (SD 0.28 g/l) elevated SAH risk in men with HR 1.15
(95% CIs 1.01e1.31) and HR 1.26 (95% CIs 1.10e1.44) per one SD increase. Age did not change these
findings.
Conclusions: An adverse lipid profile seems to elevate SAH risk similar to its effect in other cardiovascular
diseases, especially in men. Whether SAH incidence diminishes with increasing statin use remains to be
studied.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
According to prospective studies also including sudden-death
subarachnoid hemorrhages (SAHs), elevated risk for SAH associ-
ates with hypertension, smoking, increasing age, and possibly withemorrhage; TC, total choles-
L-C, low-density lipoprotein
oprotein B; TG, triglycerides;
; SES, socioeconomic status;
ence intervals; SD, standard
MAR, missing at random
th, University of Helsinki, P.O.
ohm).female sex [1e4]. Studies on lipid profile and risk for SAH are
limited, and their results are controversial [5]. A recent systematic
review [5] found only two [2,6] low-risk-of-bias prospective studies
on the effect of total cholesterol (TC) on risk for SAH, both sug-
gesting that high TC elevates the risk. However, several high-risk-
of-bias studies found an inverse or no association between TC
and SAH. In addition, few prospective studies have focused on the
association between HDL-C and SAH, and no prospective studies
exist on the association between SAH and LDL-C or apolipoproteins
[5].
Due to the high prevalence of the adverse lipid profile, its
population-attributable fraction (PAF) in SAH can reach up to 35% in
Europe in men and up to 32% in the USA in men [5]. Since statin use
is nowadays frequent and may have pleiotropic protective effects
[7], the role of adverse lipid profile in SAH can be best studied by
J. Lindbohm et al. / Atherosclerosis 274 (2018) 112e119 113utilizing prospective cohorts gathered before the widespread statin
introduction. Moreover, to obtain a comprehensive understanding
of lipid profile and SAH, irrespective of patients' access to a health
care facility, our prospective cohort also included sudden-death
SAH individuals who died outside of the hospitals. This is impor-
tant because these individuals represent 25% of all SAHs and their
exclusion may lead to limited ability to detect SAH risk factors [8].
We aimed to study associations between SAH and lipid-profile in
the pre- and post-statin era by analyzing also LDL-C, HDL-C, and
apolipoprotein levels, which may be more accurate predictors of
cardiovascular diseases than TC [9e13].
2. Materials and methods
2.1. Ethics statement
Ethical approval came from the corresponding ethics committee
according to the commonly required research procedures and
Finnish legislation for each survey, and the study was conducted
according to the World Medical Association's Declaration of Hel-
sinki on ethical principles for medical research. From 1997 on-
wards, written informed consent has been provided by each
participant [14]. The Strengthening the Reporting of Observational
studies in Epidemiology (STROBE) statement [15] guided the
reporting.
2.2. Study cohort and data collection
The study cohort and data collection methods have been
described in detail [2,16]. Briefly, the ongoing National FINRISK
study, done every five years using independent, random, and
representative population samples from different geographical
areas of Finland, provided the risk-factor data recorded at enrol-
ment between 1972 and 2007 [17]. For variables studied, experi-
enced and specially trained nurses measured blood pressure,
height, and weight, and acquired semi-fasting blood samples for
cholesterol and lipoprotein measurement after at least 4-h fasting.
The Supplementary Data describes lipid-profile measurement
methods in detail. A structured questionnaire provided data on
smoking habits, alcohol consumption, socioeconomic status (SES)
measured as years of education, and use of lipid-lowering and
antihypertensive drugs. All factors studied were measured at
enrolment for each cohort. The study cohort comprised 65,521
individuals, enrolled between 1972 and 2007.
2.3. Follow-up
The follow-up protocol has been described [2,16]. Briefly, follow-
up started at enrolment and ended at first-ever SAH, at emigration,
death, or on 31 December, 2014, whichever came first. The
nationwide Hospital Discharge Register and Causes of Death Reg-
ister identified all fatal (including out-of-hospital deaths) and non-
fatal SAHs with high accuracy [18]. Sudden-death SAHs were
defined as deaths occurring away from hospitals, on the way to a
hospital, or in an emergency room. Sudden deaths from SAH were
confirmed at autopsy, and, when necessary, a specifically trained
nosologist checked and corrected the underlying cause of death.
The follow-up was complete regarding deaths and hospitalizations
for persons who continued to live in Finland; emigration was rare
during follow-up [16].
2.4. Statistical analyses
Basic descriptives were generated by standard methods. Cor-
relations between variables were tested by Spearman's rankcorrelation coefficients. We used the Cox proportional hazard
model to calculate hazard ratios (HRs) and 95% confidence interval
(CI) in adjusted models. Because of long follow-up, we also ran
competing risks models [19] to show the associations when other
causes of death were taken into account and divided TC and HDL-C
into tertiles. Based on other prospective and population-based
studies [2,3,20], our final model included age, sex, smoking, SBP,
and TC (or one of the following: HDL-C, LDL-C, ApoA1, or ApoB).
BMI, study year, and study area were also included in the model as
possible confounders. The preliminary models examined also the
role of self-reported cholesterol-lowering drug use, alcohol con-
sumption, and SES. Because associations between risk factors and
outcomes may not be linear, we sought non-linear associations
between our variables and SAH with multivariable fractional
polynomial models [21] and with cubic splines. We found that the
inverse of HDL-C (HDL-C1) had a stronger association with SAH
than HDL-C had, and therefore our final analysis model for HDL-C
included HDL-C1. According to Schoenfeld residuals and log-log
inspection, our models met the proportional assumption criteria.
We tested multiplicative interactions with the likelihood ratio test.
PAFs were computed to provide estimates of the fraction of cases
preventable by elimination orminimization of a risk factor. To avoid
over-estimation of PAFs, these were calculated by the average
attributable fraction method, which restricts overall PAFs to 100%
[22]. The cut-off value for TC (¼5mmol/l) was adopted from the
2016 European Guidelines on Cardiovascular Disease Prevention in
Clinical Practice and the 2016 ESC/EAS Guidelines for the Man-
agement of Dyslipidaemias [12,13]. We also conducted sensitivity
analyses using pre-statin era cohorts and pre- and post-
menopausal women. All statistical analyses were done with Stata
Corp version 12.1, College Station, TX, USA, and with R 3.3.0.
2.5. Imputation model
Because study year alone explained missing values of ApoA1,
ApoB, HDL-C, and LDL-C, we used the missing at random (MAR)
assumption [23]. The percentages of missing values were for
smoking status 1.1%, SBP 1.6%, TC 1.9%, HDL-C 36.1%, TG 41.1%, LDL-C
58.8%, ApoB 65.5%, and for Apoa1 65.8% (Fig. 1A and B and
Supplementary Table I). We used multiple imputation to supple-
ment missing variables. Our imputation model included contin-
uous variables of ApoA1, ApoB, BMI, HDL-C, LDL-C, SBP, and TC and
additionally quartiles of alcohol consumption, eight categories of
smoking, three categories of SES, and use of cholesterol-lowering
drug (self-reported) as binary variable. We used linear regression
to impute continuous, ordered logistic regression to impute ordinal,
and logistic regression to impute binary variables. Because smoking
has a stronger association with SAH risk among women than
among men [4], we added an interaction term between smoking
and sex in the imputation model. In addition, our imputation
allowed for interaction between each lipoprotein variable and sex,
hypertension, or smoking. We used the imputation model based on
substantive-model compatible fully conditional specification,
which may be a better approach in nonlinear and interaction
models than is the ordinary fully conditional model [24]. Depend-
ing on convergence, we used 50 to 150 iterations to draw the
missing values and up to 80 imputations to reduce simulation error.
Convergence analyses [25] showed that our iterations were suffi-
cient and reached statistical reproducibility except for TG.
3. Results
3.1. SAH
Follow-up of 1.52 million person-years provided 543 first-ever
AB
Fig. 1. Percentage of measured (blue) and imputed (orange) values in the whole cohort and SAH cases.
(A) Cohort, (B) SAHs. Numbers in blue columns describe mean and standard deviation values of measured variables whereas numbers in orange describe corresponding values after
imputation. No imputation was used in analysis of HDL-C and total cholesterol (TC), while imputation of trigycerides (TG) did not converge. CPD, cigarettes smoked per day. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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to the whole cohort (Fig. 1A and B and Supplementary Table I),
because LDL, ApoA1, and ApoB measurements were available only
for more recent cohorts and the majority of SAHs stemmed from
older cohorts. All the results presented are from multivariable
adjusted models.
3.2. TC
The model including both sexes showed no association between
TC and SAH. When analyzed by sex, moderate evidence emergedthat each 1-SD increase in TC values elevated SAH risk in men
(HR¼ 1.15 95%CIs ¼ (1.00e1.32) but not in women. (Fig. 2 and
Supplementary Table II).3.3. HDL-C
Our models showed evidence that each 1-SD decrease in HDL-C
elevated risk for SAH (1.20 (1.14e1.26)) and this effect was seen
both in women (1.29 (1.07e1.55)) and in men (1.20 (1.14e1.27))
(Fig. 2 and Supplementary Table II).
Fig. 2. Hazard ratios and 95% confidence intervals per standard deviation increase for each lipid variable from multivariate models.
Blue, men; red, women; the y-axis shows the hazard ratio scale. TC, total cholesterol; TG, triglycerides. (For interpretation of the references to colour in this figure legend, the reader
is referred to the Web version of this article.)
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The complete case model showed no associations between LDL-
C and SAH. The model including imputations and both sexes
showed moderate evidence that each 1-SD elevation in LDL-C
elevated SAH risk 1.09 (1.00e1.19), and the association seemed
stronger in men (1.15 (1.01e1.31)). (Fig. 2 and Supplementary
Table II), but no interaction emerged.
3.5. TG
No association between TG and SAH emerged in any analysis
model (Fig. 2 and Supplementary Table II).
3.6. ApoA1 and ApoB
The complete case analysis had too few SAHs to reliably inves-
tigate associations between ApoA1 or ApoB and SAH. Analysis with
imputations suggested that each 1-SD increase in ApoA1 reduced
SAH risk (0.86 (0.78e0.95)) in the model including both sexes.
Model including imputed data and both sexes also suggested that
each 1-SD elevation in ApoB elevates SAH risk (1.14 (1.04e1.25)).
Similar to LDL-C, this association was present only in men (1.26
(1.10e1.26)) (Fig. 2 and Supplementary Table II).
3.7. Competing risk models
In line with multivariate Cox models, multivariate competing
risk models showed that in men high TC elevates SAH risk, whereas
no evidence in women emerged. However, high HDL-C decreased
SAH risk in women and men (Fig. 3A and B). Competing risks
analysis also suggested a steeper rise in SAH incidence in women
after age 65 when compared to men.
3.8. Interactions and sensitivity analysis
No strong evidence emerged of interactions between sex, hy-
pertension, or smoking and any lipid variable. When the analysis
was performed separately on women aged over 55 (presumably
post-menopausal women), the results remained essentially the
same. When all our analyses included only pre-statin era cohorts,
(time-line restricted between 1972 and 1995) the results remainedessentially the same.
3.9. Population-attributable fraction (PAFs)
We estimated PAFs by sex from a multivariable-adjusted model
including binary variables of SBP (normotensives vs hypertensives),
TC (5mmol/l as cut-off) and smoking (never-smokers vs. smoker).
In men, smoking, hypertension, and TC elevated SAH risk with very
similar PAFs of 34%, 34%, and 33%, respectively. In women, smoking
and hypertension elevated SAH risk with PAFs of 22% and 49%
(Fig. 4), indicating a relatively greater population-attributable role
for hypertension than smoking in women compared to men.
4. Discussion
Our results suggest that elevated SAH risk is associated with an
adverse lipid profile. Low HDL-C and ApoA1 elevated SAH risk in
both sexes, whereas high TC, high LDL-C, and high ApoB elevated
the risk only in men. The competing risks models were in line with
TC and HDL-C results and also suggested slightly steeper rise in SAH
incidence inwomen after age 65. No strong evidence of interactions
emerged in our analyses between lipid variables and sex, or SBP, or
smoking, or study year. Recent publications [2,5] suggest that high
TC may elevate SAH and our results provide stronger evidence of
this association. Because of the high prevalence of high TC, its PAF
in men is as high as PAFs of smoking and hypertension indicating
that, at population level, adverse lipid profile plays a major role in
SAH. Our results challenge the reliability of hospital-based studies
reporting low TC as an SAH risk factor [26e29]. Overall, up to one-
fourth of those suffering from SAH die outside hospitals or in
emergency rooms [30] and are therefore missing from hospital-
based studies. In hospital-based studies selection of controls may
lead to bias and measurement of lipid variables after SAH may lead
to reverse causality [5]. We used premorbid semi-fasting blood
samples, which provide estimates as reliable as fasting samples [31]
and included also those SAH patients dying outside of the hospital,
on the way to the hospital, or in emergency rooms.
On biological bases, adverse lipid profile may promote inflam-
mation in aneurysm walls, which can induce cell death in vascular
smooth muscle cells [32]. This hypothesis seems plausible espe-
cially because smooth muscle cells are the key regulators of the
balance between degrading and repairing processes in aneurysm
Fig. 3. Cumulative incidence of SAH from competing risks model.
(A) Tertiles of total cholesterol and (B) tertiles of HDL-C. For total cholesterol in women, the lines are on top of each other.
X-axis, age in years; Y-axis, cumulative SAH risk. The blue line represents the lowest first total cholesterol or HDL-C tertile, red second, and black third, the highest tertile. The limits
in mmol/l for tertiles are for total cholesterol in men: (1) <5.43, (2) 5.43e6.46<, (3) 6.46, and in women: (1) <5.26, (2) 5.26e6.34<, (3) 6.34. The corresponding tertiles for HDL-
C stem from a model including HDL-C1 and are: in men (1) <1.12, (2) 1.12e1.37<, (3) 1.37, and in women (1) <1.37, (2) 1.37e1.67<, (3) 1.67. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
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and hypertension) and adverse lipid profile may exist to some
extent [33,34]. Moreover, the effect of an adverse lipid profile may
differ between age-groups and differing time-points. Our results
suggest, however, that these interactions are not strong, and even
larger sample sizes would be needed to detect them.Our results are similar to findings in prospective studies on
abdominal aortic aneurysms (AAA), myocardial infarction, and
stroke [35e38]. Although pathophysiology of these diseases is
different from SAH, our results suggest that SAH belongs to
atherosclerotic diseases family. In fact, apart from diabetes [39,40]
and obesity, SAH shares themajor risk factors that are age, smoking,
Fig. 4. Population attributable fraction estimates and 95% confidence intervals of the major SAH risk factors by sex.
Blue, men; red, women. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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eases. The result of TC inmen is comparable to Systematic Coronary
Risk Estimation risk charts presented in the 2016 European
Guidelines on cardiovascular disease prevention in clinical practise
[13]. In addition, a large prospective AMORIS study [38] implied
that high HDL-C protects women against hemorrhagic stroke
(intracranial hemorrhage (ICH) and SAH combined), but unfortu-
nately the study lacked data on smoking and, as the authors re-
ported, probably included unreliable hypertension estimates. Our
associations may be stronger because we analyzed SAH separately
from ICH.
Because of long follow-up, the measured lipid values may have
changed especially after introduction of statins in 1995. However,
lipid variables did not violate proportionality in any of our model,
indicating that the association between lipids and SAH remained
the same during follow-up and that the effect of statins in this
study population is small. This could have resulted from a large
proportion of pre-statin era participants.
Even though no interaction between lipid variables and sex was
present, TC, LDL-C, and ApoB had higher HR in men. The lack of
interaction could have resulted from the limited number of SAH.
The weaker association in women may also relate to later devel-
opment of adverse lipid profile because LDL-C starts to rise in
menopause and peaks in women at 60 years of age [41]. This was
somewhat supported by our competing risks model on HDL-C,
which suggested steeper SAH incidence rise in women after age
65. Potential protecting or adverse effects of widely used hormone
replacement therapy [41e43] may confound association between
CVDs and women. However, we did not find differences in lipid-
variable HRs between pre- and postmenopausal women possibly
due to limited number of SAHs in pre-menopausal women.
Missing values are, in many studies, a common problem, and
they can reduce power and can bias the results of complete case
analysis [23]. If the imputation model is correctly built, and if the
pattern of missingness is known, multiple imputation can over-
come some of the shortcomings of complete case analysis. The
missingness of apolipoprotein and LDL-C values in our study was
only explained by study year justifying the MAR assumption [23].
HDL-C measurements were unavailable for cohorts from the 1970s,
LDL-C could not be calculated before 1992, and measurementmethods for apolipoproteins were unavailable before 1992. Our
imputation results on apolipoproteins and LDL-C tend towards a
slightly more adverse lipid profile when compared to the values
measured. This was expected, because the values were imputed to
older cohorts and is also in line with the rapid decrease in
cholesterol values in Finland since 1972 [44]. If a data set includes
many variables and observations, and if the variables correlate well
with these variables with missing values, imputations can provide
accurate results even when the proportion of missing values is
relatively high [45,46]. Our imputation results did not differ much
from measured data, indicating that they are plausible. However,
because of a large number of missing values for ApoA1, ApoB, and
LDL-C, the results for these variables should be interpreted with
caution.
The strengths of our study include: 1) long follow-up, 2) high
number of incident SAHs, 3) prospective set-up reducing risk for
information bias and reverse causality, 4) population-based cohort
reducing risk for selection bias, 5) detailed data and accurate
measurements allowing reliable subgroup analyses, 6) accurate
diagnosis of SAH [47], 7) inclusion of out-of-hospital SAH deaths,
and 8) a cohort including individuals in the period before wide-
spread statin use, 9) inclusion of SES in adjusted models.
Our study has several limitations, as well. First, we imputed a
high proportion of apolipoprotein and LDL-C values, which may
have biased results for these variables. However, HRs based on
imputations were similar to HRs based on measured values sug-
gesting that our results are plausible. Second, even though our
accuracy in aneurysmal SAH diagnosis was high with positive
predictive value of 87% [18], our study may include few traumatic
SAH cases, due to indexing errors. Such errors, if existent, however,
were more likely to weaken the associations. Third, our results are
based on one nationality, and thus may not be generalizable glob-
ally. However, contrary to the common belief, the incidence of SAH
in Finland is similar to that in other countries [30,48], suggesting
that SAH has no exceptional risk factors in Finland. Fourth, we could
not reliably study the confounding effect of statin medication on
SAH incidence. However, despite the fact that the effect of TC on
risk for SAH remained the same in the pre-statin era, we cannot
exclude the possibility that the risk-increasing effect of adverse
lipid profile would be even stronger if adjusted for statin use.
J. Lindbohm et al. / Atherosclerosis 274 (2018) 112e1191184.1. Conclusion
An atherogenic lipid profile predicts an elevated risk for SAH in
men and plays a major role at population level, whereas low HDL-C
level is associatedwith elevated risk inwomen. Given that effects of
lipid profiles on risk for SAH are challenging to study nowadays,
when statin use is common, these results with pre-statin era
analysis may perhaps be the best available evidence on the topic.
Whether the rupture risk of unruptured intracranial aneurysms
could be reduced by statin use, or whether SAH incidence di-
minishes with increasing statin use, remains to be studied.
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